Promoter Polymorphisms of TOP2A and ERCC1 Genes as Predictive Factors for Chemotherapy in Non‐small Cell Lung Cancer Patients

Cancer Medicine - United Kingdom
doi 10.1002/cam4.2743
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Predictive Factors of Severe Toxicities of Pemetrexed-Containing Chemotherapy in Patients With Non-Squamous Non-Small Cell Lung Cancer

Journal of Cancer Therapy
2017English

Chemotherapy for Non-Small Cell Lung Cancer in Elderly Patients

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

ERCC1 and Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2010English

Single Nucleotide Polymorphisms of Inflammation-Related Genes as Predictive Risk Factors of Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Factors Associated With Adherence to Chemotherapy Guidelines in Patients With Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2012English

ERCC1 Protein Expression Predicts the Response of Cisplatin-Based Neoadjuvant Chemotherapy in Non-Small-Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2008English

Associations of Polymorphisms in DNA Repair Genes and MDR1 Gene With Chemotherapy Response and Survival of Non-Small Cell Lung Cancer

PLoS ONE
Multidisciplinary
2014English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Oncology Letters
Cancer ResearchOncology
2014English

Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer

BMJ
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy